Description
The cGMP assay kit accurately measures Cyclic GMP produced by cells. The assay can be used to screen molecules that modulate the Phosphodiesterase (PDE) activity. cGMP is a major second messenger that mediates cell activities by activating various protein effectors. Cellular cGMP is synthesized by soluble guanylyl cyclases and particulate guanylyl cyclase, triggered by nitric oxide and atrial natriuretic peptide (ANP) binding respectively. The cGMP kit offers superior benefits over traditional ELISA readouts with the ease-of-use and high sensitivity of homogeneous TR-FRET assays.
HTRF assays offer many advantages over other technologies:
Homogeneous add-and-read format
No wash steps
Low background
Straightforward miniaturization from 96- or 384-well microplates to high density assay formats such as 384-well low volume and 1536-well plates
Stable signal, providing flexibility in time of readout or size of assays
Assay principle
The kit is based on a competitive format involving a specific antibody labelled with Cryptate (donor) and cGMP coupled to d2 (acceptor). cGMP produced by cells competes with d2-labelled cGMP for binding to monoclonal anti-cGMP Eu Cryptate.
Assay protocol
The cGMP assay features a streamlined protocol with only two incubation steps:
- Cell stimulation by target compounds
- cGMP detection using HTRF reagents.
This protocol requires only a single, one-hour incubation period following cell stimulation.
Nitric Oxide signaling pathway
Nitric Oxide is a key effector protein that - among other roles - is involved in cardiovascular hemostasis and vascular relaxation. In the event of a vascular stress, NO is synthesized at its location. It binds to sGC on the environing tissues, triggering the downstream decrease of Ca2+ and increase of cGMP, which in turn alters the activity of a collection of protein kinase G, cyclic nucleotide-gated ion channels and phosphodiesterases, leading to the vasodilatation of nearby vessels, blood flow increase and lowered tension.